Overexpression of p53 tumor suppressor protein in porokeratosis
- PMID: 8304757
Overexpression of p53 tumor suppressor protein in porokeratosis
Abstract
Background: p53 is a tumor suppressor nucleoprotein. Mutations of the p53 gene have been found in a variety of malignant neoplasms. Wild-type p53 has a short half-life, possibly only 20 to 30 minutes, and is not present in the nucleus at levels that are detectable with routine immunohistochemical techniques. Mutant p53 has a longer half-life, and is readily detectable with immunoperoxidase staining.
Results: We studied 17 specimens from patients with either porokeratosis of Mibelli or actinic porokeratosis, using immunoperoxidase staining with an antibody directed against the p53. There was staining of lesional keratinocyte nuclei in 16 of 17 specimens, limited in most cases to the zone between cornoid lamellae. Staining for proliferating cell nuclear antigen was increased above background levels in only six of 13 specimens.
Conclusions: The finding of p53 immunoperoxidase staining in porokeratosis suggests genetic mutation, as occurs in other cutaneous keratinocytic neoplasms, and the lack of corresponding proliferating cell nuclear antigen expression in many specimens indicates that p53 overexpression is not simply a reflection of increased cellular proliferation.
Comment in
-
Overexpression of p53 in disseminated superficial actinic porokeratosis with and without malignant degeneration.Arch Dermatol. 1995 Mar;131(3):353-4. Arch Dermatol. 1995. PMID: 7887670 No abstract available.
Similar articles
-
Abnormalities of p53 protein expression in cutaneous disorders.Arch Dermatol. 1994 Feb;130(2):225-32. Arch Dermatol. 1994. PMID: 8304762 Review.
-
p53 alterations in porokeratosis.J Cutan Pathol. 2003 Aug;30(7):455-8. doi: 10.1034/j.1600-0560.2003.00097.x. J Cutan Pathol. 2003. PMID: 12859744
-
Overexpression of p53 in disseminated superficial actinic porokeratosis with and without malignant degeneration.Arch Dermatol. 1995 Mar;131(3):353-4. Arch Dermatol. 1995. PMID: 7887670 No abstract available.
-
Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors.J Dermatol. 2006 May;33(5):319-25. doi: 10.1111/j.1346-8138.2006.00076.x. J Dermatol. 2006. PMID: 16700663
-
Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: Update on the genetics and clinical expression of porokeratosis.J Am Acad Dermatol. 2010 Nov;63(5):886-91. doi: 10.1016/j.jaad.2009.07.038. Epub 2010 May 6. J Am Acad Dermatol. 2010. PMID: 20451293 Review.
Cited by
-
A case of genital porokeratosis and review of literature.Indian J Dermatol. 2015 Mar-Apr;60(2):217. doi: 10.4103/0019-5154.152587. Indian J Dermatol. 2015. PMID: 25814761 Free PMC article.
-
Porokeratosis and malignancy: Incidental or causal association?Indian Dermatol Online J. 2015 Nov-Dec;6(6):452-3. Indian Dermatol Online J. 2015. PMID: 26753153 Free PMC article. No abstract available.
-
[77-year-old female with persisting erythematous and scaly plaques on the extremities and upper trunk : Preparation for the medical specialist examination: Part 20].Hautarzt. 2018 Nov;69(Suppl 2):165-168. doi: 10.1007/s00105-018-4281-8. Hautarzt. 2018. PMID: 30374539 German. No abstract available.
-
MicroRNA-874 targets phosphomevalonate kinase and inhibits cancer cell growth via the mevalonate pathway.Sci Rep. 2022 Nov 2;12(1):18443. doi: 10.1038/s41598-022-23205-w. Sci Rep. 2022. PMID: 36323841 Free PMC article.
-
Cordycepin Ameliorates Psoriasis-Like Skin Lesion by Regulating p53/MDM2 Feedback Loop.Mol Biotechnol. 2025 Jun;67(6):2481-2492. doi: 10.1007/s12033-024-01211-9. Epub 2024 Jun 24. Mol Biotechnol. 2025. PMID: 38914920
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous